The short version of Thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
As a result, to be able to separate mixtures more efficiently, a subsequent LC analysis must employ very different separation selectivity relative to the first column. Another requirement to effectively use 2D liquid chromatography, according to Bushey and Jorgenson, is to employ highly orthogonal techniques which means that the two separation techniques must be as different as possible.
Bacterial metabolic traits play important roles in maintaining ecological processes and supporting human activities. For example, diazotrophs have the ability to fix nitrogen gas using the enzyme nitrogenase. This trait, which can be found in bacteria of most metabolic types listed above, leads to the ecologically important processes of denitrification, sulfate reduction, and acetogenesis, respectively. Bacterial metabolic processes are important drivers in biological responses to pollution; for example, sulfate-reducing bacteria are largely responsible for the production of the highly toxic forms of mercury (methyl- and dimethylmercury) in the environment. Nonrespiratory anaerobes use fermentation to generate energy and reducing power, secreting metabolic by-products (such as ethanol in brewing) as waste. Facultative anaerobes can switch between fermentation and different terminal electron acceptors depending on the environmental conditions in which they find themselves.
== Discovery == The technique was invented in 1955 by Grant Henry Lathe and Colin R Ruthven, working at Queen Charlotte's Hospital, London. They later received the John Scott Award for this invention. While Lathe and Ruthven used starch gels as the matrix, Jerker Porath and Per Flodin later introduced dextran gels; other gels with size fractionation properties include agarose and polyacrylamide. A short review of these developments has appeared. There were also attempts to fractionate synthetic high polymers; however, it was not until 1964, when J. C. Moore of the Dow Chemical Company published his work on the preparation of gel permeation chromatography (GPC) columns based on cross-linked polystyrene with controlled pore size, that a rapid increase of research activity in this field began. It was recognized almost immediately that with proper calibration, GPC was capable to provide molar mass and molar mass distribution information for synthetic polymers. Because the latter information was difficult to obtain by other methods, GPC came rapidly into extensive use.
Sources: en.wikipedia.org
=== Contestants === Caleb King, Pastry Sous Chef from Seattle, Washington Ciarra Roberts, Pastry Sous Chef from Denver, Colorado Elizabeth Suwanski, Project Manager and Home Baker from Chicago Illinois Kyle Caulkins, Pastry Chef from Charleston, South Carolina Kyle Olson, Executive Pastry Chef from Columbus, Ohio Lisa Pak, Home Bakery Owner from New York City, New York Marian Mulero, Owner of Chef Marian Cakes & Dessert Tables from Miami, Florida 8th - Baindu Squire, Cake Artist from New Orleans, Louisiana 9th - Justin Giordano, Cake Artist from New York City, New York 10th - Katie Shegda, Pastry Chef from Greenville, South Carolina
The U.S. Congress extended American citizenship to all Native Americans in 1924; this law has been held to include the indigenous peoples of Alaska. A hospital was built in Unalaska in 1933 by the U.S. Bureau of Indian Affairs.
=== November 2005 === -173 detainees found in an Iraqi government bunker in Baghdad were found starved, beaten and tortured. -Colin Powell's former Chief of Staff, Colonel Lawrence Wilkerson, stated in an interview with Amy Goodman on November 22 that:
== Organisational structure == The NNPC's business operations are managed through Strategic Business and Corporate Services Units (SBUs/CSUs) in diverse locations across Nigeria. The NNPC Group comprises the NNPC Board, the group managing director's office, Five directorates as listed below. Each of the directorate is headed by an executive vice president (EVP). Its divisions are headed by chiefs, while its subsidiary companies are headed by managing directors. NNPC has several subsidiaries, two partly owned subsidiaries and 16 associated companies. Directorates:
Sources: en.wikipedia.org
In molecular biology, and more importantly high-throughput DNA sequencing, a chimera is a single DNA sequence originating when multiple transcripts or DNA sequences get joined. Chimeras can be considered artifacts and be filtered out from the data during processing to prevent spurious inferences of biological variation. However, chimeras should not be confused with chimeric reads, which are generally used by structural variant callers to detect structural variation events and are not always an indication of the presence of a chimeric transcript or gene. In a different context, the deliberate creation of artificial chimeras can also be a useful tool in molecular biology. For example, in protein engineering, "chimeragenesis" (forming chimeras between proteins that are encoded by homologous cDNAs) is one of the "two major techniques used to manipulate cDNA sequences". For gene fusions that occur through natural processes, see chimeric genes and fusion genes.
Stability of isotopes is affected by the ratio of protons to neutrons, and also by presence of certain magic numbers of neutrons or protons which represent closed and filled quantum shells. These quantum shells correspond to a set of energy levels within the shell model of the nucleus; filled shells, such as the filled shell of 50 protons for tin, confers unusual stability on the nuclide. As in the case of tin, a magic number for Z, the atomic number, tends to increase the number of stable isotopes for the element. Just as electrons have the lowest energy state when they occur in pairs in a given orbital, nucleons (both protons and neutrons) exhibit a lower energy state when their number is even, rather than odd. This stability tends to prevent beta decay (in two steps) of many even–even nuclides into another even–even nuclide of the same mass number but lower energy (and of course with two more protons and two fewer neutrons), because decay proceeding one step at a time would have to pass through an odd–odd nuclide of higher energy. Such nuclei thus instead undergo double beta decay (or are theorized to do so) with half-lives several orders of magnitude larger than the age of the universe. This makes for a larger number of stable even–even nuclides, which account for 150 of the 251 total. Stable even–even nuclides number as many as three isobars for some mass numbers, and up to seven isotopes for some atomic numbers.
=== A10BD Combinations of oral blood glucose lowering drugs === A10BD01 Phenformin and sulfonylureas A10BD02 Metformin and sulfonylureas A10BD03 Metformin and rosiglitazone A10BD04 Glimepiride and rosiglitazone A10BD05 Metformin and pioglitazone A10BD06 Glimepiride and pioglitazone A10BD07 Metformin and sitagliptin A10BD08 Metformin and vildagliptin A10BD09 Pioglitazone and alogliptin A10BD10 Metformin and saxagliptin A10BD11 Metformin and linagliptin A10BD12 Pioglitazone and sitagliptin A10BD13 Metformin and alogliptin A10BD14 Metformin and repaglinide A10BD15 Metformin and dapagliflozin A10BD16 Metformin and canagliflozin A10BD17 Metformin and acarbose A10BD18 Metformin and gemigliptin A10BD19 Linagliptin and empagliflozin A10BD20 Metformin and empagliflozin A10BD21 Saxagliptin and dapagliflozin A10BD22 Metformin and evogliptin A10BD23 Metformin and ertugliflozin A10BD24 Sitagliptin and ertugliflozin A10BD25 Metformin, saxagliptin and dapagliflozin A10BD26 Metformin and lobeglitazone A10BD27 Metformin, linagliptin and empagliflozin A10BD28 Metformin and teneligliptin A10BD29 Sitagliptin and dapagliflozin A10BD30 Gemigliptin and dapagliflozin A10BD31 Metformin, sitagliptin and dapagliflozin A10BD32 Glimepiride and dapagliflozin A10BD33 Pioglitazone and dapagliflozin A10BD34 Metformin and enavogliflozin
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.